UCB SA and Antengene Corp. Ltd. have entered into a license agreement that grants UCB a worldwide exclusive license to further develop, manufacture and commercialize ATG-201.
Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.
CD47, or integrin-associated protein, is a ubiquitously expressed cell surface protein that is overexpressed in many solid tumors and hematologic malignancies, including multiple myeloma, with higher levels associated with poor prognosis. In a recent study published in iScience, researchers from Westlake University (China) engineered an oncolytic vaccinia virus encoding an anti-mouse CD47 nanobody (OVV-aCD47nb) that combines direct oncolysis with localized CD47-SIRPα axis blockade.
A therapeutic strategy based on alternative splicing of the MECP2 gene could restore protein levels in Rett syndrome, a neurological disorder caused by mutations in that gene. Scientists at Baylor College of Medicine have successfully tested this approach both in vitro in neurons from Rett patients that produce some functional protein, correcting the altered gene expression and improving neuronal functions, and in vivo in mice.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have jointly identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors for use in the treatment of cancer.
CHA University has identified chalcone derivatives acting as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors potentially useful for the treatment of Alzheimer’s disease.
Rongchang Pharmaceutical (Zibo) Co. Ltd. has synthesized nitrogen-containing fused ring compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and diabetes.
Dice Alpha Inc. has disclosed interleukin-17A (IL-17A) inhibitors designed for use in the treatment of psoriasis, rheumatoid arthritis, multiple sclerosis and more.
RSS
